All Stories

  1. Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines
  2. EASL Clinical Practice Guidelines on nutrition in chronic liver disease
  3. Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival
  4. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French–Spanish experience
  5. Colangitis biliar primaria
  6. Primary biliary cholangitis and bone disease
  7. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history
  8. Osteoporosis in chronic liver disease
  9. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
  10. Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment
  11. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome
  12. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis
  13. Advances in treatment options for patients with primary biliary cholangitis
  14. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response
  15. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis
  16. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis
  17. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial
  18. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study
  19. Juan Rodés. A successful and extraordinary life of a visionary hepatologist
  20. An appealing new agent for treating cholestatic pruritus
  21. Novel Treatment Strategies for Primary Biliary Cholangitis
  22. Expert clinical management of autoimmune hepatitis in the real world
  23. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease
  24. Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers
  25. Colangitis biliar primaria
  26. Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis
  27. Enteroendocrine cells are a potential source of serum autotaxin in men
  28. Preface
  29. Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid
  30. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy
  31. Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists
  32. Changing nomenclature for PBC: From ‘cirrhosis’ to ‘cholangitis’
  33. Changing Nomenclature for PBC: From ‘Cirrhosis’ to ‘Cholangitis’
  34. Changing Nomenclature for PBC: From ‘Cirrhosis’ to ‘Cholangitis’
  35. Changing nomenclature for PBC: From ‘cirrhosis’ to ‘cholangitis’
  36. Changing nomenclature for PBC: From ‘cirrhosis’ to ‘cholangitis’
  37. Changing Nomenclature for PBC: From ‘Cirrhosis’ to ‘Cholangitis’
  38. Changing nomenclature for PBC: From ‘cirrhosis’ to ‘cholangitis’
  39. Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’
  40. Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1
  41. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis
  42. Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
  43. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study
  44. Bone Disease in Patients with Cirrhosis
  45. TRAIL-producing NK cells contribute to liver injury and related fibrogenesis in the context of GNMT deficiency
  46. Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study
  47. Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis
  48. Extrahepatic Malignancies in Primary Biliary Cirrhosis: A Comparative Study at Two European Centers
  49. Old and Novel Therapies for Primary Biliary Cirrhosis
  50. Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid?
  51. Extracorporeal liver support in severe alcoholic hepatitis
  52. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis
  53. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid
  54. Ursodeoxycholic acid protects osteoblastic cells from bilirubin and lithocholic acid induced apoptosis
  55. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
  56. Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells
  57. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial
  58. Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease
  59. Osteoporosis en la cirrosis hepática
  60. Sex Differences Associated with Primary Biliary Cirrhosis
  61. Tuberculosis Is Not a Risk Factor for Primary Biliary Cirrhosis: A Review of the Literature
  62. Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?
  63. Effects of bilirubin and sera from jaundiced patients on osteoblasts: Contribution to the development of osteoporosis in liver diseases
  64. Hepatitis aguda alcohólica
  65. Fibratos en el tratamiento de la cirrosis biliar primaria
  66. Colangiopatía IgG4. Características clínicas y diagnóstico diferencial
  67. Patients with cirrhosis and ascites have false values of bone density
  68. Proteomic Analysis of Polypeptides Captured from Blood during Extracorporeal Albumin Dialysis in Patients with Cholestasis and Resistant Pruritus
  69. Management of osteoporosis in liver disease
  70. Colangitis esclerosante primaria: diagnóstico, pronóstico y tratamiento
  71. Enfermedad de Caroli
  72. Print and Media Review
  73. Reply:
  74. Liver and bone
  75. Characterization of peptides and proteins in commercial HSA solutions
  76. Treatment of resistant pruritus from cholestasis with albumin dialysis: Combined analysis of patients from three centers
  77. Low Bone Mass and Severity of Cholestasis Affect Fracture Risk in Patients With Primary Biliary Cirrhosis
  78. The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts
  79. Lithocholic acid downregulates vitamin D effects in human osteoblasts
  80. The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts
  81. Characterization of peptides and proteins in commercial HSA solutions
  82. Utilidad del ácido ursodeoxicólico en la colangitis esclerosante primaria
  83. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: Comparative analysis from two centers
  84. New ELISA for Detecting Primary Biliary Cirrhosis-Specific Antimitochondrial Antibodies
  85. High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue
  86. Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure
  87. Excellent long-term survival in patients with primary biliary cirrhosis treated with ursodeoxycholic acid
  88. Historia natural de la cirrosis biliar primaria
  89. Simplified criteria for the diagnosis of autoimmune hepatitis
  90. Osteoporosis in Primary Biliary Cirrhosis: Pathogenesis and Treatment
  91. 874 INCIDENCE AND RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PRIMARY BILIARY CIRRHOSIS
  92. 123 PRESENTATION AND NATURAL HISTORY OF PRIMARY BILIARY CIRRHOSIS IN SPAIN: EXPERIENCE OVER 35 YEARS
  93. Serum paraoxonase-1 in chronic alcoholics: Relationship with liver disease
  94. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis
  95. Treatment of bone disorders in liver disease
  96. Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid
  97. Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature
  98. Prevalence and Mechanisms of Hyperhomocysteinemia in Chronic Alcoholics
  99. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis
  100. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis
  101. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis
  102. Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis
  103. Colangitis esclerosante primaria
  104. Tratamiento de las complicaciones óseas
  105. Extracorporeal Albumin Dialysis: A Procedure for Prolonged Relief of Intractable Pruritus in Patients with Primary Biliary Cirrhosis
  106. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis
  107. Primary Biliary Cirrhosis Specific Antinuclear Antibodies in Patients from Spain
  108. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis
  109. Colangitis esclerosante primaria
  110. Natural history of primary biliary cirrhosis
  111. Alendronate Is More Effective Than Etidronate for Increasing Bone Mass in Osteopenic Patients With Primary Biliary Cirrhosis
  112. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis
  113. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis
  114. Expected developments in hepatology
  115. Cerebral consequences of alcoholic liver disease
  116. Hyperhomocysteinemia in chronic alcoholism. Relationship to liver damage
  117. The molecular adsorbent recirculating system (MARS) improves systemic hemodynamics and hepatic encephalopathy in patients with severe alcoholic hepatitis
  118. Molecular adsorbent recirculating system: a new procedure for relieving intractable pruritus in patients with primary biliary cirrhosis
  119. Duration and severity of the disease but not menopausal status are the main risk factors for osteoporosis in primary biliary cirrhosis
  120. Genetic polymorphisms of alcohol metabolizing enzymes do not influence the development of alcoholic liver disease
  121. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis
  122. Cholangiocarcinoma in Primary Sclerosing Cholangitis: Risk Factors and Clinical Presentation
  123. Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis
  124. Hepatocellular Carcinoma in Primary Biliary Cirrhosis: Similar Incidence To That in Hepatitis C Virus–Related Cirrhosis
  125. Long-term ursodeoxycholic acid treatment delays progression of mild primary biliary cirrhosis
  126. Factors influencing histological progression of early primary biliary cirrhosis. Effect of ursodeoxycholic acid
  127. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus–related cirrhosis
  128. Collagen type Iα1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis
  129. S-Adenosylmethionine prevents hepatic tocopherol depletion in carbon tetrachloride-injured rats
  130. Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis
  131. Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis
  132. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: A multicenter randomized trial
  133. Enhanced DNA Binding and Activation of Transcription Factors NF-kappa B and AP-1 by Acetaldehyde in HEPG2 Cells
  134. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial
  135. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development
  136. Prevalencia y factores asociados a la presencia de esteatosis hepática en varones adultos aparentemente sanos
  137. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial
  138. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations
  139. High Bilirubin Levels Interfere with Serum Tartrate-Resistant Acid Phosphatase Determination: Relevance as a Marker of Bone Resorption in Jaundiced Patients
  140. Effects of silymarin in alcoholic patients with cirrhosis of the liver
  141. Collagen‐Related Markers of Bone Turnover Reflect the Severity of Liver Fibrosis in Patients with Primary Biliary Cirrhosis
  142. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial
  143. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial
  144. Management of primary biliary cirrhosis: osteoporosis
  145. Zinc Administration Improves Gastric Alcohol Dehydrogenase Activity and First‐Pass Metabolism of Ethanol in Alcohol‐Fed Rats
  146. Carbohydrate‐Deficient Transferrin as a Marker of Alcohol Consumption in Male Patients with Liver Disease
  147. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: Preliminary results after 2 years
  148. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis
  149. Effects of S-adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis
  150. Effects of ethanol feeding and malnutrition on collagen synthesizing and degrading enzymes in rat pancreas
  151. Serum Amino-Terminal Propeptide of Type III Procollagen Levels in Chronic Pancreatitis
  152. Mycobacteria - related to the aetiopathogenesis of primary biliary cirrhosis?
  153. Vertebral fractures and osteopenia in chronic alcoholic patients
  154. Bone mass improves in alcoholics after 2 years of abstinence
  155. Acetaldehyde activates the promoter of the mouse α2(I) collagen gene
  156. Acetaldehyde activates the promoter of the mouse $alpha;2(I) collagen gene*1
  157. Fibrogenic and collagenolytic activity in carbon-tetrachloride-injured rats: beneficial effects of zinc administration
  158. Epidemiology of primary sclerosing cholangitis in Spain
  159. Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis
  160. Disulfiram-induced hepatitis. Report of four cases and review of the literature
  161. Determinants of Ethanol and Acetaldehyde Metabolism in Chronic Alcoholics
  162. Drinking in the Injury Event: A Comparison of Emergency Room Populations in the United States, Mexico, and Spain
  163. S-adenosylmethionine treatment prevents carbon tetrachloride—inducedS-adenosylmethionine synthetase inactivation and attenuates liver injury
  164. Influence of dietary zinc on hepatic collagen and prolyl hydroxylase activity in alcoholic rats
  165. Sodium fluoride prevents bone loss in primary biliary cirrhosis
  166. Primary Biliary Cirrhosis and Sclerosing Cholangitis
  167. Are hepatitis C virus antibodies involved in chronic liver diseases other than non-A, non-B hepatitis?
  168. Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: A randomized controlled trial
  169. Reply
  170. Anemia in primary biliary cirrhosis (PBC). A new prognostic feature
  171. Hepatitis C virus antibodies in chronic alcoholic patients: Association with severity of liver injury
  172. Liver diseases associated with autoantibodies directed to nuclear envelope components
  173. Alcoholic foamy degeneration in Spain. Prevalence and clinico‐pathological features
  174. COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS
  175. Comparative study of aminoglycoside nephrotoxicity in normal rats and rats with experimental cirrhosis
  176. Autoantibodies against nuclear envelope-associated proteins in primary biliary cirrhosis
  177. Esophageal dysfunction in primary biliary cirrhosis
  178. Analysis of factors predicting early seroconversion to anti-HBe in HBeAg-positive chronic hepatitis B
  179. Cyanamide hepatotoxicity. Incidence and clinicopathological features
  180. Portal hypertension in primary biliary cirrhosis
  181. Histological course of alcoholic hepatitis
  182. Measurement of fibrosis in needle liver biopsies: Evaluation of a colorimetric method
  183. Lymphocytotoxic antibodies in primary biliary cirrhosis
  184. Acute Thallium Poisoning: An Evaluation of Different Forms of Treatment
  185. Nonoliguric acute renal failure in an intensive care unit
  186. Primary Biliary Cirrhosis Associated with HLA—DRw3